ASH 2020 | CLL advances: What will we see more of in 2021?
John Seymour
• 7 Dec 2020
John Seymour, MBBS, FRACP, Peter MacCallum Cancer Centre, East Melbourne, Australia, discusses exciting advances in chronic lymphocytic leukemia (CLL) presented at ASH 2020. He notes a strong theme of increased exploration of novel-novel combinations. However, Prof. Seymour believes that longer-term follow-up and an improved understanding of the impact of sequencing are vital for the validation of these therapies. Advances in cellular therapies and non-covalent BTK inhibitors are highlighted as major advances that will have a greater role in the coming years. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
